1. Alessandra Pavesio (2006). Regenerative Medicine. Nanomedicine
2. C. Hadjipanayis,A. Bouras,S. Chang (2013). Applications of Multifunctional Nanoparticles in Malignant Brain Tumours. EUR ASSOC NEUROONCOL MAG. EUR ASSOC NEUROONCOL MAG, 1-7.
3. Yu Cheng,Ramin Morshed,Brenda Auffinger,Alex Tobias,Maciej Lesniak (2013). Multifunctional nanoparticles for brain tumor imaging and therapy. Advanced Drug Delivery Reviews, 66, 42-57.
4. Chih-hsien Gann ting,Hsin-ell wang (2009). Cancer Nanotargeted Radiopharmaceuticals for Tumor Imaging and Therapy. Anticancer Research, 29, 4107-4118.
5. L. Muldoon,P. Tratnyek,P. Jacobs,N. Doolittle,G. Christoforidis (2006). Imaging and Nanomedicine for Diagnosis and Therapy in the Central Nervous System: Report of the Eleventh Annual Blood-Brain Barrier Disruption Consortium Meeting. AJNR Am J Neuroradiol, 27, 715-721.
6. Tennyson Joseph D Meyers,Clemens Doane,James Burda,Basilion (2013). Nanoparticles for imaging and treating brain cancer. Nanomedicine, 8, 123-143.
7. M. Amiji (2006). Nanotechnology for Cancer Therapy; Amiji DMM. Nanotechnology for Cancer Therapy
8. Natalie Praetorius,Tarun Mandal (2007). Engineered Nanoparticles in Cancer Therapy. Recent Patents on Drug Delivery & Formulation, 1(1), 37-51.
9. Juillerat-Jeanneret L (2008). The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drugnanoparticles?. Drug Discov Today, 13, 1099-1106.
10. S. Moghimi,A. Hunter,J. Murray (2005). Nanomedicine: current status and future prospects. The FASEB Journal, 19(3), 311-330.
11. Loredana Serpe (2006). Conventional Chemotherapeutic Drug Nanoparticles for Cancer Treatment. In: S. CS, Kumar R
12. Ranendra Saha,Sekar Vasanthakumar,Girish Bende,Movva Snehalatha (2010). Nanoparticulate drug delivery systems for cancer chemotherapy. Molecular Membrane Biology, 27(7), 215-231.
13. Frank Alexis,Eric Pridgen,Robert Langer,Omid Farokhzad (2010). Drug Delivery: Nanoparticle Technologies for Cancer Therapy. Handbook of Experimental Pharmacology, 55-86.
14. Y. Pathak (2009). Recent Developments in Nanoparticulate Drug Delivery Systems. In: Yashwant Pathak, Deepak Thassu, editors. Drug Delivery Nanoparticles Formulation and Characterization. NY: Informa Healthcare USA. Drug Delivery Nanoparticles Formulation and Characterization, 1-15.
15. A. Guyton,Je (2005). Textbook of Medical Physiology.
16. Massimo Masserini (2013). Nanoparticles for Brain Drug Delivery. ISRN Biochemistry, 2013, 1-18.
17. Sarin H,Kanevsky AS,Wu H,Brimacombe KR,Fung SA (2008). Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. Journal of Translational Medicine, 6(1), 80.
18. F. Giulio,Lawrence Paciotti,Tamarkin (2007). Nanoparticulate Drug Delivery Systems; Deepak Thassu, Michel Deleers, Pathak Y.
19. (SCENIHR) SCoEaNIHR (2006). the appropriateness of existing methodologies to assess the potential risks associated with engineered and adventitious products of nanotechnologies.
20. Amrita Dikpati,Madgulkar,J. Sanjay,Kshirsagar,Bhalekar,Chahal,AS (2012). Targeted Drug Delivery to CNS using Nanoparticles. JAPS, 2
21. K. Swatantra,Aditi Kushwaha,A. RastogI,Satyawan Rai,Singh (2012). Novel Drug Delivery System for Anticancer Drug. International Journal of Pharm Tech Research, 4, 542-553.
22. Xiaobin Wu,Robert Zhao,Lee (2007). Lipid-Based Nanoparticulate Drug Delivery Systems. Nanoparticulate Drug Delivery Systems, 92.
23. Oktay Tacar,Pornsak Sriamornsak,Crispin Dass (2013). Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. Journal of Pharmacy and Pharmacology, 65(2), 157-170.
24. Regulon (2009). BBB (blood‐brain barrier).
25. Gelperina SE,Khalansky AS,Skidan IN,Smirnova ZS,Bobruskin AI (2002). Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicology Letters, 126(2), 131-141.
26. Jörg Kreuter (2001). Nanoparticulate systems for brain delivery of drugs. Advanced Drug Delivery Reviews, 47(1), 65-81.
27. Nazila Kamaly,Zeyu Xiao,Pedro Valencia,Aleksandar Radovic-Moreno,Omid Farokhzad (2011). Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chemical Society Reviews, 41(7), 2971.
28. Bärbel Volker Wagner,Sibylle Gaisser,anne-Katrin Bock (2006). Nanomedicine: Drivers for development and possible impacts Luxembourg: European Commission Joint Research Centre Institute for Prospective Technological Studies.
29. Ernest Azzopardi,Elaine Ferguson,David Thomas (2013). The enhanced permeability retention effect: a new paradigm for drug targeting in infection. Journal of Antimicrobial Chemotherapy, 68(2), 257-274.
30. H. Choi,W. Liu,P. Misra,E. Tanaka,J. Zimmer (2007). Renal clearance of quantum dots. Nat Biotechnol, 25, 1165-1170.
31. Pathak Y,Thassu D,Deleers M (2007). Pharmaceutical Applications of Nanoparticulate Drug-Delivery Systems. In: Thassu D, Deleers M, Pathak Y, editors. Nanoparticulate Drug Delivery Systems. NY: Informa Healthcare USA. Nanoparticulate Drug Delivery Systems, 185-212.
32. Costantino L,D. B (2012). Review Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?. Drug Discovery Today, 17(7-8), 367-378.
33. He H,Li Y,Jia XR,Du J,Ying X (2011). PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials, 32(2), 478-487.
34. Yan H,Wang L,Wang J,Weng X,Lei H (2012). Two-Order Targeted Brain Tumor Imaging by Using an Optical/Paramagnetic Nanoprobe across the Blood Brain Barrier. ACS Nano, 6(1), 410-420.
35. Letfullin RR,Iversen CB,TF G (2011). Modeling nanophotothermal therapy: kinetics of thermal ablation of healthy and cancerous cell organelles and gold nanoparticles. Nanomedicine: Nanotechnology, Biology and Medicine, 7(2), 137-145.
36. Hadjipanayis CG,Machaidze R,Kaluzova M,Wang L,Schuette AJ (2010). (2010 ) EGFRvIII antibodyconjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Research, 70(15), 6303-6312.
37. Khlebtsov N,L. D (2011). Review Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem. Soc. Rev, 40(3), 1647-1671.
38. A. Freitas,J. (2005). Current Status of Nanomedicine and Medical Nanorobotics Institute for Molecular Manufacturing, Palo Alto, California, USA. J Comput Theor Nanosci, 2, 1-25.
39. Gao X,Yang L,Petros JA,Marshall FF,Simons JW (2005). Review In vivo molecular and cellular imaging with quantum dots. Current Opinion in Biotechnology, 16(1), 63-72.
40. Park JY,Baek MJ,Choi ES,Woo S,Kim JH (2009). Paramagnetic Ultrasmall Gadolinium Oxide Nanoparticles as Advanced T1 MRI Contrast Agent: Account for Large Longitudinal Relaxivity, Optimal Particle Diameter, and In Vivo T1 MR Images. ACS Nano, 3(11), 3663-3669.
41. Veiseh O,Sun C,Gunn J,Kohler N,Gabikian P (2005). Optical and MRI Multifunctional Nanoprobe for Targeting Gliomas. Nano Letters, 5(6), 1003-1008.
42. Hadjipanayis CG,Machaidze R,Kaluzova M,Wang L,Schuette AJ (2010). EGFRvIII antibodyconjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res, 70(15), 6303-6312.
43. Gref R,Lück M,Quellec P,Marchand M,Dellacherie E (2000). 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces, 18(3-4), 301-313.
44. Sousa F,Mandal S,Garrovo C,Astolfo A,Bonifacio A (2010). Functionalized gold nanoparticles: a detailed in vivo multimodal microscopic brain distribution study. Nanoscale, 2(12), 2826.
45. Popovtzer R,Agrawal A,Kotov NA,Popovtzer A,Balter J (2008). (2008 ) Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Letters, 8(12), 4593-4596.
46. Foy SP,Manthe RL,Foy ST,Dimitrijevic S,Krishnamurthy N (2010). (2010 ) Optical imaging and magnetic field targeting of magnetic nanoparticles in tumors. ACS Nano, 4(9), 5217-5224.
47. Dyer M,Hinchcliffe M,Watts P,Casille J,Jabbal-Gill I (2002). Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles Pharm Res.
